Weeks after Global Healthcare Pharma issued a recall of ErziCare eye drops, the U.S. Food and Drug Administration (FDA) launched an investigation into the pharmaceutical company’s labs and found dozens of issues and violations of Current Good Manufacturing Practice (CGMP). The violations included poor cleaning procedures, discolored clothing in cleanrooms, and “black, brown greasy deposits” on machinery used to fill product into bottles. Officials reported that the lab’s manufacturing process “lacked assurance of product sterility.”
Shortly after the first recall was announced, the first EzriCare eye drop lawsuit was filed against Global Pharma Healthcare by a Florida woman who developed “unrelenting pain in her eyes” after using the eye drops.